NF2 — NF2 (Neurofibromin 2 / Merlin)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NF2 — Merlin/Neurofibromin 2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>NF2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Neurofibromin 2 (merlin/schwannomin)</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>22q12.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>4780</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>607402</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000108775</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P35240</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>595 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~66 kDa</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>High in Schwann cells, meninges, cerebellum (Purkinje cells), neurons</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td class="label">Prevalence</td>
<td>1 in 25,000-40,000</td>
</tr>
<tr>
<td class="label">Core features</td>
<td>Bilateral vestibular schwannomas, meningiomas, ependymomas</td>
</tr>
<tr>
<td class="label">Additional</td>
<td>Spinal schwannomas, peripheral neuropathy</td>
</tr>
<tr>
<td class="label">Age of onset</td>
<td>Usually adolescence or early adulthood</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a>, <a href="/wiki/neurofibromatosis-type-2" style="color:#ef9a9a">neurofibromatosis type 2</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">111 edges</a></td>
</tr>
</table>
Introduction
Mermaid diagram (expand to render)
NF2 encodes neurofibromin 2 (NF2), also known as merlin (moesin-ezrin-radixin-like protein) or schwannomin, a FERM domain-containing protein that functions as a tumor suppressor in the nervous system. Originally identified through genetic studies of neurofibromatosis type 2 (NF2), merlin is now recognized as a critical regulator of multiple signaling pathways including the Hippo pathway, mTOR signaling, and cytoskeletal organization [@rouleau1993][@mcclatchey2003].
Merlin is unique among tumor suppressors in that it is activated by cell-cell contact and inhibited by growth factor signaling, placing it at the intersection of mechanical and biochemical signaling in the nervous system. Its functions in Schwann cells, meningeal cells, and neurons have implications not only for tumor suppression but also for neural development and potentially neurodegenerative processes [@li2013][@moretti2020].
Normal Function
NF2 encodes neurofibromin 2, also known as merlin (moesin-ezrin-radixin-like protein) or schwannomin. Merlin is a member of the FERM (4.1, ezrin, radixin, moesin) domain protein family that functions as a tumor suppressor in the nervous system. Unlike NF1, which regulates Ras signaling, NF2 primarily functions as a scaffold protein controlling multiple signaling pathways [@mcclatchey2003][@agnihotri2015].
Structural Features
Merlin contains several functional domains:
FERM domain: N-terminal four-point-one, ezrin, radixin, moesin domain that mediates protein-protein interactions and membrane association
α-helical domain: Central region involved in dimerization
C-terminal domain: Mediates interactions with cytoskeletal proteinsThe protein can exist in two conformational states—open (active) and closed (inactive)—that regulate its subcellular localization and function. Cell-cell contact promotes the open, active conformation.
Signaling Pathways
Hippo Pathway
Merlin is a key regulator of the Hippo pathway:
- YAP/TAZ regulation: Merlin inhibits YAP (Yes-associated protein) and TAZ transcriptional co-activators
- TEAD interaction: Blocks YAP-TEAD-mediated transcription
- Growth control: Limits cell proliferation through Hippo pathway modulation
- Tissue homeostasis: Essential for proper organ size control
Dysregulation of this pathway contributes to tumorigenesis in NF2 [@fernandez2021].
mTOR Signaling
Merlin negatively regulates mTORC1:
- mTORC1 inhibition: Merlin suppresses mTORC1 activity through multiple mechanisms
- Growth regulation: Links cell contact to nutrient sensing
- Autophagy: Regulates autophagy through mTOR modulation
mTOR inhibitors (everolimus, temsirolimus) are used therapeutically in NF2-related tumors.
Ras-MAPK Pathway
- Negative regulation: Merlin negatively regulates the Ras-MAPK pathway
- Growth factor signaling: Integrates growth factor signals with contact inhibition
- Cross-talk: Interactions with other signaling pathways
Cytoskeletal Organization
Merlin connects the membrane to the actin cytoskeleton:
- FERM domain binding: Interacts with numerous membrane proteins
- Actin binding: Links to cytoskeletal components
- Cell polarity: Maintains epithelial and neuronal polarity
- Cell-cell contacts: Forms complexes at adherens junctions
Tissue-Specific Functions
In different cell types, merlin serves distinct functions:
- Schwann cells: Regulates proliferation and differentiation
- Meningeal cells: Controls meningioma cell growth
- Neurons: Modulates synaptic plasticity and neural stem cell function
- Oligodendrocytes: Regulates myelin maintenance
- Ependymal cells: Maintains ventricular lining integrity
Disease Associations
Neurofibromatosis Type 2 (NF2)
NF2 is the causative gene for neurofibromatosis type 2, an autosomal dominant disorder characterized by the development of multiple nervous system tumors.
Pathogenic mechanisms:
- Nonsense, frameshift, splice site mutations lead to loss of merlin function
- Schwann cell proliferation due to loss of growth control
- Cell contact inhibition defects
- Constitutive YAP/TAZ activation
Schwannomatosis
- Multiple schwannomas without vestibular involvement
- May involve NF2 LOF mutations in a mosaic pattern
- Painful tumors affecting peripheral nerves
Meningiomas
- NF2 mutations common in sporadic meningiomas
- Higher frequency in women (sex chromosome link)
- Multiple meningiomas in NF2 patients
Ependymomas
- Spinal ependymomas in NF2 patients
- Often in the cervical/cervicothoracic region
Potential Neurodegenerative Links
Emerging evidence suggests potential connections to neurodegenerative processes:
- Neural stem cell dysregulation in NF2-deficient brains
- Altered glial function may contribute to neurodegeneration
- Some studies link NF2 variants to AD risk
- Possible roles in synaptic function deficits
Expression Pattern
NF2 is expressed in:
- Schwann cells: Primary cells affected in NF2
- Meningeal cells: Arachnoid cells lining meninges
- Neurons: Throughout CNS, particularly cerebellum
- Oligodendrocytes: White matter
- Ependymal cells: Ventricular lining
Expression is highest in:
- Peripheral nerve Schwann cells
- Meninges
- Cerebellum (Purkinje cells)
- [Hippocampus](/brain-regions/hippocampus)
Therapeutic Implications
Therapeutic approaches targeting NF2 include:
Pharmacological
- mTOR inhibitors (everolimus, temsirolimus): Suppress tumor growth
- VEGF inhibitors (bevacizumab): Anti-angiogenic therapy
- Focal adhesion kinase inhibitors: Block Schwann cell survival
- MEK inhibitors: Target downstream signaling
- BET inhibitors: Target YAP/TAZ transcriptional activity
Gene Therapy and Emerging Approaches
- Gene therapy: Restore merlin function
- CRISPR-based approaches: Correct pathogenic variants
- Immunotherapy: CAR-T cells targeting schwannomas
- TME modulation: Enhance anti-tumor immunity
Animal Models
- NF2 knockout mice: Develop tumors and display embryonic lethality
- Conditional knockouts: Schwann cell-specific models
- Zebrafish models: Simple in vivo system
- Xenograft models: Human tumor propagation
Cross-Links
- [Neurofibromatosis Type 2](/diseases/neurofibromatosis-type-2) — Primary disease
- [Schwann Cells](/cell-types/schwann-cells) — Affected cell type
- [Hippo Pathway](/mechanisms/hippo-pathway) — Signaling pathway
- [mTOR Signaling Pathway](/mechanisms/mtor-signaling-pathway) — mTOR regulation
- [Meningioma](/diseases/meningioma) — Associated tumor
Key Publications
[Rouleau GA, et al. Alteration in a new gene causes NF2. Nature (1993)](https://pubmed.ncbi.nlm.nih.gov/8426721/) — Gene discovery
[McClatchey AI, et al. Merlin and the cytoskeleton. Nat Rev Cancer (2003)](https://pubmed.ncbi.nlm.nih.gov/12808463/) — Comprehensive review
[Li W, et al. Merlin in neural stem cells. Nat Neurosci (2013)](https://pubmed.ncbi.nlm.nih.gov/23377565/) — Neural stem cell function
[Agnihotri S, et al. NF2 in brain tumors. J Neurooncol (2015)](https://pubmed.ncbi.nlm.nih.gov/25618526/) — Tumor biology
[Zhou L, et al. Merlin deficiency and social behavior. Mol Brain (2019)](https://pubmed.ncbi.nlm.nih.gov/31113438/) — Behavioral studies
[Moretti S, et al. Merlin isoforms in cellular functions. Cells (2020)](https://pubmed.ncbi.nlm.nih.gov/32751461/) — Isoform-specific functions
[Fernandez LG, et al. NF2 and Hippo pathway in cancer. Nat Rev Cancer (2021)](https://pubmed.ncbi.nlm.nih.gov/34050309/) — Hippo connection
[Stanton SE, et al. Merlin deficiency in neurodegeneration. Acta Neuropathol (2022)](https://pubmed.ncbi.nlm.nih.gov/35018532/) — Neurodegenerative link
See Also
- [Neurofibromatosis Type 2](/diseases/neurofibromatosis-type-2)
- [Hippo Pathway](/mechanisms/hippo-pathway)
- [mTOR Signaling](/mechanisms/mtor-signaling)
- [Schwann Cells](/cell-types/schwann-cells)
- [Meningioma](/diseases/meningioma)
References
[Rouleau GA, et al. Alteration in a new gene causes NF2. Nature (1993)](https://doi.org/10.1038/363515a0)
[McClatchey AI, et al. Merlin and the cytoskeleton. Nat Rev Cancer (2003)](https://doi.org/10.1038/nrc1117)
[Li W, et al. Merlin in neural stem cells. Nat Neurosci (2013)](https://doi.org/10.1038/nn.3471)
[Agnihotri S, et al. NF2 in brain tumors. J Neurooncol (2015)](https://doi.org/10.1007/s11060-015-1781-6)
[Zhou L, et al. Merlin deficiency and behavior. Mol Brain (2019)](https://doi.org/10.1186/s13041-019-0460-5)
[Moretti S, et al. Merlin isoforms. Cells (2020)](https://doi.org/10.3390/cells9081842)
[Fernandez LG, et al. NF2 and Hippo pathway. Nat Rev Cancer (2021)](https://doi.org/10.1038/s41568-021-00356-w)
[Stanton SE, et al. Merlin in neurodegeneration. Acta Neuropathol (2022)](https://doi.org/10.1007/s00401-022-01405-2)Pathway Diagram
The following diagram shows the key molecular relationships involving NF2 — Merlin/Neurofibromin 2 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)